Confluence Investment Management LLC Boosts Position in Haleon plc (NYSE:HLN)

Confluence Investment Management LLC boosted its stake in Haleon plc (NYSE:HLN) by 2.0% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 83,694 shares of the company’s stock after acquiring an additional 1,623 shares during the period. Confluence Investment Management LLC’s holdings in Haleon were worth $691,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. EverSource Wealth Advisors LLC increased its stake in Haleon by 13.8% during the first quarter. EverSource Wealth Advisors LLC now owns 16,204 shares of the company’s stock worth $138,000 after purchasing an additional 1,962 shares during the period. Cetera Advisors LLC increased its stake in Haleon by 524.3% during the first quarter. Cetera Advisors LLC now owns 81,991 shares of the company’s stock worth $696,000 after purchasing an additional 68,857 shares during the period. Cetera Investment Advisers increased its stake in Haleon by 106.3% during the first quarter. Cetera Investment Advisers now owns 233,788 shares of the company’s stock worth $1,985,000 after purchasing an additional 120,447 shares during the period. Atria Investments Inc increased its stake in Haleon by 5.7% during the first quarter. Atria Investments Inc now owns 181,557 shares of the company’s stock worth $1,541,000 after purchasing an additional 9,746 shares during the period. Finally, B. Riley Wealth Advisors Inc. grew its position in shares of Haleon by 23.2% during the first quarter. B. Riley Wealth Advisors Inc. now owns 29,324 shares of the company’s stock worth $246,000 after buying an additional 5,519 shares in the last quarter. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have commented on HLN. Berenberg Bank began coverage on shares of Haleon in a research report on Wednesday, June 5th. They issued a “buy” rating on the stock. HSBC began coverage on shares of Haleon in a report on Wednesday, April 17th. They issued a “buy” rating on the stock. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy”.

Haleon Stock Down 0.7 %

NYSE:HLN traded down $0.07 during midday trading on Monday, hitting $9.56. 4,073,051 shares of the company were exchanged, compared to its average volume of 5,215,472. The company has a fifty day simple moving average of $8.65 and a 200 day simple moving average of $8.43. Haleon plc has a fifty-two week low of $7.70 and a fifty-two week high of $9.73. The company has a current ratio of 1.04, a quick ratio of 0.73 and a debt-to-equity ratio of 0.53. The company has a market capitalization of $43.65 billion, a PE ratio of 31.87, a price-to-earnings-growth ratio of 2.69 and a beta of 0.24.

Haleon (NYSE:HLN) last posted its quarterly earnings data on Thursday, August 1st. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The business had revenue of $3.50 billion during the quarter, compared to analyst estimates of $3.55 billion. Haleon had a net margin of 9.71% and a return on equity of 19.85%. During the same quarter in the prior year, the firm posted $0.08 earnings per share. As a group, equities analysts anticipate that Haleon plc will post 0.47 earnings per share for the current fiscal year.

Haleon Cuts Dividend

The company also recently announced a semi-annual dividend, which will be paid on Thursday, September 19th. Stockholders of record on Friday, August 16th will be issued a $0.0514 dividend. This represents a dividend yield of 1.6%. The ex-dividend date is Friday, August 16th. Haleon’s payout ratio is 33.33%.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.